NewAmsterdam Pharma (NAMS)
Develops oral obicetrapib for adjunct LDL-C lowering.
$25.60
At close+0.68 (+2.73%)
Something off on this page? Send us feedback.
Next report
Nov 4, 2026
estimated · in 62 days
EPS estimate
−$0.50
Revenue estimate
$7.5M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.95−$0.49−$0.15−$0.41−$0.63−$0.40−$0.52Pending
Estimate−$0.48−$0.45−$0.52−$0.38−$0.43−$0.46−$0.48−$0.50
Surprise−97.9%−8.9%+71.2%−7.9%−45.1%+13.0%−7.9%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$13.2M$3.2M$22.4M$348.0K$32.0K$3.0M$3.7MPending
Estimate$1.8M$1.5M$3.5M$2.4M$2.9M$1.7M$2.8M$7.5M
Surprise+653.3%+121.1%+542.0%−85.5%−98.9%+72.0%+30.7%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.50 | — | — |
| Aug 2026 | −$0.48 | −$0.52 | −7.9% |
| May 2026 | −$0.46 | −$0.40 | +13.0% |
| Feb 2026 | −$0.43 | −$0.63 | −45.1% |
| Nov 2025 | −$0.38 | −$0.41 | −7.9% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Feb 2024 | |||
| Aug 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Oct 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$0.50 | — | — | $7.5M | — | — | — |
| Aug 5, 2026 | −$0.48 | −$0.52 | −7.9% | $2.8M | $3.7M | +30.7% | −0.5% |
| May 7, 2026 | −$0.46 | −$0.40 | +13.0% | $1.7M | $3.0M | +72.0% | +11.1% |
| Feb 18, 2026 | −$0.43 | −$0.63 | −45.1% | $2.9M | $32.0K | −98.9% | −3.2% |
| Nov 5, 2025 | −$0.38 | −$0.41 | −7.9% | $2.4M | $348.0K | −85.5% | −2.8% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||||||
| Aug 6, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 26, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 7, 2024 | |||||||
| May 8, 2024 | |||||||
| Mar 29, 2024 | |||||||
| Feb 28, 2024 | |||||||
| Aug 7, 2023 | |||||||
| Jun 30, 2023 | |||||||
| Mar 31, 2023 | |||||||
| Oct 18, 2022 | |||||||
| Jun 30, 2022 | |||||||
| Mar 30, 2022 | |||||||
| Dec 31, 2021 | |||||||
| Sep 30, 2021 | |||||||
| Jun 30, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 | |||||||